The Netherlands
Scinvivo B.V., founded in 2016 and headquartered in The Netherlands, is revolutionizing the diagnostics of bladder cancer with its proprietary technology. With the slogan "Optical biopsy for bladder cancer diagnostics", Scinvivo addresses significant limitations in current imaging technologies.
Existing techniques often misclassify healthy tissue as cancerous in 30% of cases, complicating the surgical removal of tumors and failing to gauge the invasion depth—an essential factor for treatment planning. The company's cutting-edge technology enhances diagnostic accuracy, reducing unnecessary interventions, patient burdens, and associated costs.
Positioned at the intersection of Biotechnology, Health Care, Information Technology, and Medical Devices, Scinvivo recently secured a €4.70M investment from NLC and Santec Corporation in a venture round on 21 February 2024, demonstrating strong investor confidence in its potential to transform bladder cancer diagnostics.
